tiprankstipranks
Trending News
More News >

Emergent BioSolutions Secures $62.4M ASPR Contract Modification

Story Highlights
  • Emergent BioSolutions secured a $62.4 million contract modification for BAT®.
  • The contract highlights the U.S. government’s commitment to stockpiling medical countermeasures.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Emergent BioSolutions Secures $62.4M ASPR Contract Modification

Don’t Miss TipRanks’ Half-Year Sale

Emergent Biosolutions ( (EBS) ) has provided an update.

On June 23, 2025, Emergent BioSolutions announced a $62.4 million contract modification with the Administration for Strategic Preparedness and Response (ASPR) for the supply of BAT®, a botulism antitoxin. This contract modification underscores the U.S. government’s commitment to stockpiling medical countermeasures and highlights Emergent’s role in strengthening global emergency preparedness and public health protection.

The most recent analyst rating on (EBS) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.

Spark’s Take on EBS Stock

According to Spark, TipRanks’ AI Analyst, EBS is a Neutral.

Emergent Biosolutions is facing significant financial challenges with declining revenues and profitability, which heavily weigh on its overall score. Technical indicators are mixed but slightly positive, and while the earnings call highlighted some improvements, the valuation remains poor. Corporate events present both legal challenges and growth opportunities.

To see Spark’s full report on EBS stock, click here.

More about Emergent Biosolutions

Emergent BioSolutions is a company focused on delivering protective and life-saving solutions for health threats such as smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies.

Average Trading Volume: 1,220,898

Technical Sentiment Signal: Sell

Current Market Cap: $337.6M

See more insights into EBS stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1